睑板腺癌治疗的研究进展

Recent advances on treatment of meibomian gland carcinoma

睑板腺癌是一种起源于睑板腺的恶性肿瘤,居眼睑恶性肿瘤的第四位。因其临床表现多样,常常被误诊为其它良性或低度恶性病变而延误诊治。肿瘤具有侵袭性,局部复发及淋巴结转移不难发现。上述各种因素为肿瘤的早期诊断、早期治疗带来了巨大的困难。虽然以手术为主、冷冻、放疗为辅的综合性治疗仍为睑板腺癌的首选,但随着手术及放疗方式的改进,睑板腺癌相关基因的发现、局部使用化疗药物成为可能以及光动力疗法的出现等都为睑板腺癌的治疗创造了无限的可能。我们就睑板腺癌治疗的新进展作一概述。

Meibomian gland carcinoma is a malignant tumor that arises from meibomian glands. It is also the fourth most common malignant neoplasm of the eyelid. Historically, this neoplasm was notorious for masquerading as other benign and less malignant lesions, resulting in delays in diagnosis and treatment. Because these tumors can behave in an aggressive manner, local recurrence and regional lymph node metastasis are common. These factors create difficulties for the early detection and diagnosis. Although based on surgery, cryotherapy, radiation therapy, supplemented by a comprehensive treatment of meibomian gland carcinoma is still the first choice, but with improvements in surgery and radiotherapy methods, meibomian gland carcinoma-related gene discovery, local use of chemotherapy drugs have become possible, as well as the emergence of photodynamic therapy and so on for the treatment of meibomian gland carcinoma has created endless possibilities. This article makes a brief overview of the recent advances on treatment of meibomian gland carcinoma.